Literature DB >> 19246450

Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus.

Julie Qi Hang1, Yanli Yang, Seth F Harris, Vincent Leveque, Hannah J Whittington, Sonal Rajyaguru, Gloria Ao-Ieong, Matthew F McCown, April Wong, Anthony M Giannetti, Sophie Le Pogam, Francisco Talamás, Nick Cammack, Isabel Nájera, Klaus Klumpp.   

Abstract

The binding affinity of four palm and thumb site representative non-nucleoside inhibitors (NNIs) of HCV polymerase NS5B to wild-type and resistant NS5B polymerase proteins was determined, and the influence of RNA binding on NNI binding affinity was investigated. NNIs with high binding affinity potently inhibited HCV RNA polymerase activity and replicon replication. Among the compounds tested, HCV-796 showed slow binding kinetics to NS5B. The binding affinity of HCV-796 to NS5B increased 27-fold over a 3-h incubation period with an equilibrium Kd of 71 +/- 2 nm. Slow binding kinetics of HCV-796 was driven by slow dissociation from NS5B with a k(off) of 4.9 +/- 0.5 x 10(-4) s(-1). NS5B bound a long, 378-nucleotide HCV RNA oligonucleotide with high affinity (Kd = 6.9 +/- 0.3 nm), whereas the binding affinity was significantly lower for a short, 21-nucleotide RNA (Kd = 155.1 +/- 16.2 nm). The formation of the NS5B-HCV RNA complex did not affect the slow binding kinetics profile and only slightly reduced NS5B binding affinity of HCV-796. The magnitude of reduction of NNI binding affinity for the NS5B proteins with various resistance mutations in the palm and thumb binding sites correlated well with resistance -fold shifts in NS5B polymerase activity and replicon assays. Co-crystal structures of NS5B-Con1 and NS5B-BK with HCV-796 revealed a deep hydrophobic binding pocket at the palm region of NS5B. HCV-796 interaction with the induced binding pocket on NS5B is consistent with slow binding kinetics and loss of binding affinity with mutations at amino acid position 316.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19246450      PMCID: PMC2708848          DOI: 10.1074/jbc.M808889200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus.

Authors:  S Bressanelli; L Tomei; A Roussel; I Incitti; R L Vitale; M Mathieu; R De Francesco; F A Rey
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Authors:  Anita Y M Howe; Huiming Cheng; Ian Thompson; Srinivas K Chunduru; Steve Herrmann; John O'Connell; Atul Agarwal; Rajiv Chopra; Alfred M Del Vecchio
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

4.  Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.

Authors:  Tammy T Nguyen; Adam T Gates; Lester L Gutshall; Victor K Johnston; Baohua Gu; Kevin J Duffy; Robert T Sarisky
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Investigating the origin of the slow-binding inhibition of HCV NS3 serine protease by a novel substrate based inhibitor.

Authors:  Yaya Liu; Ayda Saldivar; Joshua Bess; Larry Solomon; Chih-Ming Chen; Rakesh Tripathi; Leo Barrett; Paul L Richardson; Akhteruzzaman Molla; William Kohlbrenner; Warren Kati
Journal:  Biochemistry       Date:  2003-07-29       Impact factor: 3.162

6.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

Authors:  R A Spence; W M Kati; K S Anderson; K A Johnson
Journal:  Science       Date:  1995-02-17       Impact factor: 47.728

7.  The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.

Authors:  Matthew F McCown; Sonal Rajyaguru; Sophie Le Pogam; Samir Ali; Wen-Rong Jiang; Hyunsoon Kang; Julian Symons; Nick Cammack; Isabel Najera
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

8.  Characterization of the metal ion binding properties of the hepatitis C virus RNA polymerase.

Authors:  Isabelle Bougie; Sébastien Charpentier; Martin Bisaillon
Journal:  J Biol Chem       Date:  2002-11-27       Impact factor: 5.157

Review 9.  Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.

Authors:  Pierre L Beaulieu
Journal:  Curr Opin Investig Drugs       Date:  2007-08

10.  Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Licia Tomei; Sergio Altamura; Linda Bartholomew; Antonino Biroccio; Alessandra Ceccacci; Laura Pacini; Frank Narjes; Nadia Gennari; Monica Bisbocci; Ilario Incitti; Laura Orsatti; Steven Harper; Ian Stansfield; Michael Rowley; Raffaele De Francesco; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  31 in total

1.  Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.

Authors:  Leen Delang; Inge Vliegen; Mathy Froeyen; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

2.  Pyridine Carboxamides: Potent Palm Site Inhibitors of HCV NS5B Polymerase.

Authors:  Cliff C Cheng; Xiaohua Huang; Gerald W Shipps; Yu-Sen Wang; Daniel F Wyss; Kyle A Soucy; Chuan-Kui Jiang; Sony Agrawal; Eric Ferrari; Zhiqing He; H-C Huang
Journal:  ACS Med Chem Lett       Date:  2010-08-17       Impact factor: 4.345

3.  Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype-specific manner.

Authors:  Leiyun Weng; Yuichi Hirata; Masaaki Arai; Michinori Kohara; Takaji Wakita; Koichi Watashi; Kunitada Shimotohno; Ying He; Jin Zhong; Tetsuya Toyoda
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

Review 4.  Drug-target residence time: critical information for lead optimization.

Authors:  Hao Lu; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2010-07-19       Impact factor: 8.822

5.  Impact of mutations on the allosteric conformational equilibrium.

Authors:  Patrick Weinkam; Yao Chi Chen; Jaume Pons; Andrej Sali
Journal:  J Mol Biol       Date:  2012-12-07       Impact factor: 5.469

Review 6.  Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities.

Authors:  Tetsuro Shimakami; Robert E Lanford; Stanley M Lemon
Journal:  Curr Opin Pharmacol       Date:  2009-09-15       Impact factor: 5.547

7.  Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.

Authors:  Aaditya Bhatt; K R Gurukumar; Amartya Basu; Maulik R Patel; Neerja Kaushik-Basu; Tanaji T Talele
Journal:  Eur J Med Chem       Date:  2011-08-26       Impact factor: 6.514

8.  Mechanisms of activity and inhibition of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Stefan Reich; Ralph Peter Golbik; René Geissler; Hauke Lilie; Sven-Erik Behrens
Journal:  J Biol Chem       Date:  2010-03-01       Impact factor: 5.157

9.  A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes.

Authors:  Melanie Schmitt; Nathalie Scrima; Danijela Radujkovic; Célia Caillet-Saguy; Philip C Simister; Peter Friebe; Oliver Wicht; Rahel Klein; Ralf Bartenschlager; Volker Lohmann; Stéphane Bressanelli
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

10.  1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Authors:  Origène Nyanguile; Benoit Devogelaere; Leen Vijgen; Walter Van den Broeck; Frederik Pauwels; Maxwell D Cummings; Hendrik L De Bondt; Ann M Vos; Jan M Berke; Oliver Lenz; Geneviève Vandercruyssen; Katrien Vermeiren; Wendy Mostmans; Pascale Dehertogh; Frédéric Delouvroy; Sandrine Vendeville; Koen VanDyck; Koen Dockx; Erna Cleiren; Pierre Raboisson; Kenneth A Simmen; Gregory C Fanning
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.